214665 Finsbury WWP pp37-pp50 6 15 09 1:30 PM Page 44 Finsbury Worldwide Pharmaceutical Trust PLC Annual Report 2009 44 Notes to the Financial Statements continued 13.
Also during the year a total of 2,679,750 shares which were previously held in treasury have been cancelled.
The Company also allotted a total of 13,070 shares for total consideration of 61,000 on 4 August 2008 as a result of certain holders of the Companys warrants exercising their subscription rights.
Holders of warrants have the right to subscribe for the number of shares of the Company equal to the number of warrants held at a price of 464p per share on 31 July 2009, this being the last such subscription date.
NET ASSET VALUE PER SHARE 2009 2008 000 000 Net asset value per share basic 635.9p 486.6p Net asset value per share diluted 600.5p 482.4p The net asset value per share is based on the assets attributable to equity shareholders of 263,017,000 2008: 224,783,000 and on the number of shares in issue at the year end of 41,361,431 excluding shares held in treasury 2008: 46,190,161.
The diluted net asset value per share assumes all outstanding warrants are exercised at 464p resulting in assets attributable to equity shareholders of 312,877,000 2008: 274,703,000 and on the resultant number of shares of 52,107,041 2008: 56,948,841.
RECONCILIATION OF OPERATING RETURN TO NET CASH OUTFLOW FROM OPERATING ACTIVITIES 2009 2008 000 000 Gains loss before finance costs and taxation 65,341 15,083 Capital gain loss before finance costs and taxation 62,027 17,657 Revenue return before finance costs and taxation 3,314 2,574 Expenses charged to capital 2,436 2,323 Increase decrease in accrued income 422 6 Decrease in other debtors 391 Increase decrease in creditors and accruals 220 112 Net taxation suffered on investment income 740 568 Net cash outflow from operating activities 61 332
